Skip to main content

Table 2 Least squares mean change in primary and secondary clinical outcomes in mixed-effects model repeated measurement statistical analysis

From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

At week 104 Placebo Gantenerumab 105 mg Gantenerumab 225 mg
LS mean
(95% CI)
LS mean
(95% CI)
p Value vs placebo LS mean
(95% CI)
p Value vs placebo
Primary endpoint
 CDR-SB
  Change from baseline 1.60 (1.28, 1.91) 1.69 (1.37, 2.01) 1.73 (1.42, 2.04)
  Difference from placebo 0.10 (−0.35, 0.54) 0.67 0.18 (−0.28, 0.63) 0.45
Secondary endpoint
 ADAS-Cog 13
  Change from baseline 5.77 (4.54, 6.99) 5.14 (3.91, 6.38) 5.54 (4.21, 6.87)
  Difference from placebo −0.62 (−2.34, 1.09) 0.48 −0.27 (−2.23, 1.70) 0.79
 FAQ
  Change from baseline 4.70 (3.71, 5.68) 5.93 (4.93, 6.93) 4.57 (3.58, 5.55)
  Difference from placebo 1.23 (−0.16, 2.62) 0.08 −0.27 (−1.72, 1.18) 0.72
 MMSE
  Change from baseline −2.93 (−3.50, −2.35) −3.02 (−3.60, −2.44) −2.73 (−3.33, −2.14)
  Difference from placebo −0.10 (−0.90, 0.71) 0.81 0.34 (−0.54, 1.22) 0.45
  1. Abbreviations: ADAS-Cog 13 Alzheimer’s Disease Assessment Scale–Cognitive subscale, CDR-SB Clinical Dementia Rating Sum of Boxes, FAQ Functional Activities Questionnaire, LS Least squares, MMSE Mini Mental State Examination